The transformation of intellectual property (IP) management within commercial companies is driving the adoption of new practices and technologies to more closely align IP objectives with growth strategies, unlock greater portfolio value, and support strategic decision-making across enterprises. Nowhere is that more critical than at the nexus of IP and Research and Development (R&D), where organizations are applying IP insights to accelerate scientific breakthroughs and identify potential risks to commercialization earlier in the product lifecycle.
Missing critical IP information during R&D can lead to misallocated resources, potential patent entanglements downstream, and delays in commercialization.
Join Gene Quinn, patent attorney and founder of IPWatchdog.com, for a conversation about IP, R&D, and facilitating innovation to streamline commercialization. Joining the conversation will be Jerzy Klosin, Fellow at the Dow Chemical Company, Christine Goddard, a principal at Fish & Richardson with expertise in strategic patent portfolio management particularly for pharmaceutical companies, and Matthew McBride, Director of IP Services for CAS.
The panel will share different perspectives about how you can make greater use of IP information to guide R&D. During our webinar the panel will address: